메뉴 건너뛰기
New England Journal of Medicine
Volumn 365, Issue 10, 2011, Pages 952-953
New options in anticoagulation for atrial fibrillation
Author keywords

[No Author keywords available]
Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN;
EID: 80052603528     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1107516     Document Type: Editorial
Times cited : (30)
References (7)
  • 1
    • 80052576183 scopus 로고    scopus 로고
    • Anticoagulants in atrial fibrillation
    • Loscalzo J, Schafer AI, eds. 3rd ed. Philadelphia: Lippincott Williams & Wilkins
    • Ezekowitz M.D., Surashi S.K. Anticoagulants in atrial fibrillation. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2003:1066-1076
    • (2003) Thrombosis and Hemorrhage , pp. 1066-1076
    • Ezekowitz, M.D.1    Surashi, S.K.2
  • 2
    • 45949095568 scopus 로고    scopus 로고
    • Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
    • DOI 10.1378/chest.08-0678
    • Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:Suppl:546S-592S. (Pubitemid 351892972)
    • (2008) Chest , vol.133 , Issue.6 SUPPL. 6
    • Singer, D.E.1    Albers, G.W.2    Dalen, J.E.3    Fang, M.C.4    Go, A.S.5    Halperin, J.L.6    Lip, G.Y.H.7    Manning, W.J.8
  • 3
    • 80052592404 scopus 로고    scopus 로고
    • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
    • Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891
    • (2011) N Engl J Med , vol.365 , pp. 883-891
    • Patel, M.R.1    Mahaffey, K.W.2    Garg, J.3
  • 4
    • 70349306707 scopus 로고    scopus 로고
    • Dabigatran versus warfarin in patients with atrial fibrillation
    • Erratum, N Engl J Med 2010;363:1877
    • Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151[Erratum, N Engl J Med 2010;363:1877.]
    • (2009) N Engl J Med , vol.361 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 5
    • 37149001785 scopus 로고    scopus 로고
    • The interpretation of lack of evidence of a difference in efficacy: Equivalence trials and the treatment of fungal infections
    • Moran J.L., Solomon P.J. The interpretation of lack of evidence of a difference in efficacy: Equivalence trials and the treatment of fungal infections. Crit Care Resusc 2003;5:216-223
    • (2003) Crit Care Resusc , vol.5 , pp. 216-223
    • Moran, J.L.1    Solomon, P.J.2
  • 7
    • 79958126202 scopus 로고    scopus 로고
    • Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial
    • Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011;123:2363-2372
    • (2011) Circulation , vol.123 , pp. 2363-2372
    • Eikelboom, J.W.1    Wallentin, L.2    Connolly, S.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.